Clinical Trials Browser

Phase 1/2 × Nivolumab × Tumor-Agnostic × Clear all

NCT04317105 2026-03-18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT07276373 2026-02-27

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT01968109 2026-01-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT04021043 2025-12-03

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Phase 1/2 Completed

51 enrolled 16 charts

Neoplasm Metastasis

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT04761198 2025-03-17

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1/2 Completed

76 enrolled 20 charts

Neoplasm Metastasis

NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Phase 1/2 Completed

25 enrolled 9 charts

Neoplasms

NCT02904226 2023-07-03

ICONIC

Phase 1/2 Completed

242 enrolled 29 charts

Neoplasms

NCT05175235 2023-03-03

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Phase 1/2 Unknown

Neoplasms

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

Neoplasms

NCT03363776 2020-12-19

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Phase 1/2 Terminated

10 enrolled 11 charts

Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms

NCT03792724 2019-01-03

INTRUST

Phase 1/2 Unknown

Neoplasms